See every side of every news story
Published loading...Updated

Ozempic Set to Become More Affordable, Accessible in Canada — Raising Concerns of Drug Abuse

SINGAPORE, JUL 11 – Wegovy, a semaglutide-based drug approved for obesity, complements lifestyle changes and addresses a chronic condition affecting 11.6% of adults in Singapore, health authorities said.

  • Patients using Ozempic report a complete loss of sex drive, stating they have 'zero sex drive' after nearly two years on the medication.
  • Users have expressed frustration, claiming that their libido has been 'completely crushed' due to Ozempic.
  • Sue Decotiis, MD, states that reduced sex drive may relate to general fatigue experienced at the beginning of treatment.
  • Ozempic, a GLP-1 medication, has previously been linked to side effects like severe vomiting and gastroparesis.
Insights by Ground AI
Does this summary seem wrong?

18 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 46% of the sources are Center
46% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Le Journal de Quebec broke the news in Quebec City, Canada on Thursday, July 10, 2025.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.